title: Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
abstract: Essentials Platelet-Factor (F) VIII gene therapy is a promising treatment in hemophilia A. This study aims to evaluate if platelet-FVIII expression would increase the risk for thrombosis. Targeting FVIII expression to platelets does not induce or elevate thrombosis risk. Platelets expressing FVIII are neither hyper-activated nor hyper-responsive.
  
  
  
  Background Targeting factor (F) VIII expression to platelets is a promising gene therapy approach for hemophilia A, and is successful even in the presence of inhibitors. It is well known that platelets play important roles not only in hemostasis, but also in thrombosis and inflammation. Objective To evaluate whether platelet-FVIII expression might increase thrombotic risk and thereby compromise the safety of this approach. Methods In this study, platelet-FVIII-expressing transgenic mice were examined either in steady-state conditions or under prothrombotic conditions induced by inflammation or the FV Leiden mutation. Native whole blood thrombin generation assay, rotational thromboelastometry analysis and ferric chloride-induced vessel injury were used to evaluate the hemostatic properties. Various parameters associated with thrombosis risk, including D-dimer, thrombin-antithrombin complexes, fibrinogen, tissue fibrin deposition, platelet activation status and activatability, and platelet-leukocyte aggregates, were assessed. Results We generated a new line of transgenic mice that expressed 30-fold higher levels of platelet-expressed FVIII than are therapeutically required to restore hemostasis in hemophilic mice. Under both steady-state conditions and prothrombotic conditions induced by lipopolysaccharide-mediated inflammation or the FV Leiden mutation, supratherapeutic levels of platelet-expressed FVIII did not appear to be thrombogenic. Furthermore, FVIII-expressing platelets were neither hyperactivated nor hyperactivatable upon agonist activation. Conclusion We conclude that, in mice, more than 30-fold higher levels of platelet-expressed FVIII than are required for therapeutic efficacy in hemophilia A are not associated with a thrombotic predilection.
authors: Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.
authors: C K
authors: CK
authors: Baumgartner
authors: Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.
authors: J G
authors: JG
authors: Mattson
authors: Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.
authors: H
authors: H
authors: Weiler
authors: Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.|Medical College of Wisconsin, Milwaukee, WI, USA.|Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI, USA.|MACC Fund Research Center, Milwaukee, WI, USA.
authors: Q
authors: Q
authors: Shi
authors: Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.|Medical College of Wisconsin, Milwaukee, WI, USA.|Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI, USA.
authors: R R
authors: RR
authors: Montgomery
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000378:metabolism; D001777:Blood Coagulation / Q000235:genetics; D001792:Blood Platelets / Q000378:metabolism; D003029:Coagulants / Q000627:therapeutic use; D005165:Factor V / Q000235:genetics; D005169:Factor VIII / Q000235:genetics / Q000378:metabolism*; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods*; D006467:Hemophilia A / Q000235:genetics* / Q000628:therapy*; D006487:Hemostasis; D006801:Humans; D007962:Leukocytes / Q000378:metabolism; D008070:Lipopolysaccharides; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009154:Mutation; D010641:Phenotype; D015539:Platelet Activation; D013917:Thrombin / Q000378:metabolism; D013927:Thrombosis / Q000235:genetics*
chemical_list: D000991:Antithrombins; D003029:Coagulants; D005338:Fibrin Fibrinogen Degradation Products; D008070:Lipopolysaccharides; C095381:factor V Leiden; C036309:fibrin fragment D; C427184:recombinant factor VIII SQ; C078147:F8 protein, human; D005165:Factor V; D005169:Factor VIII; D005337:Fibrin; D005340:Fibrinogen; D013917:Thrombin
keywords: factor VIII; gene therapy; hemophilia A; platelet; thrombosis